Tag: gross proceeds

Boise, Idaho, July 06, 2026 (GLOBE NEWSWIRE) -- Idaho Copper Corporation (“Idaho Copper” and the “Company”) (NYSE American: COPR, COPR WS), a critical minerals developer advancing the flagship CuMo copper-molybdenum-silver project in Idaho, today announced the closing of its underwritten public offering of shares of its common stock and warrants at a public offering price of $4.85 per share and accompanying warrant for gross proceeds of approximately $18,000,000, before deducting underwriting discounts and offering expenses. In addition, Idaho Copper has granted the underwriters a 45-day option to purchase up to an additional 556,800 shares of common stock and/or warrants to cover over-allotments at the public offering price, if any. The offering also included the purchase by the underwriters of 556,800 warrants in connection with the partial exercise by the underwriters of their over-allotment option.

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

INDIANAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, today announced the completion of the sale of City Center, a multi-level mixed-use asset in White Plains, New York, for gross proceeds of $50 million.

HAMBURG, Germany and MUNICH, June 26, 2026 (GLOBE NEWSWIRE) -- XCHG Limited ("XCharge" or the "Company") (Nasdaq: XCH), an integrated EV charging and energy solutions company, today announced that it has entered into a securities purchase agreement with a single global institutional investor for the purchase and sale of 7,000,000 of the Company’s American depositary shares (the “ADSs”) in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.375 million, before deducting placement agent commissions and other offering expenses.

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.